The effect of a new medicine (giredestrant or GDC-9545) in patients with ER+ positive breast cancer

A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

  • Breast Cancer
Trial Status:

Completed

This trial runs in
Cities
  • Antwerpen
  • Auderghem
  • Aurora
  • Barcelona
  • Boston
  • Darlinghurst
  • Donostia
  • Edegem
  • Hasselt
  • Lille
  • Liverpool
  • London
  • Lone Tree
  • Madrid
  • Murdoch
  • Namur
  • New York
  • Rennes
  • Saint-Cloud
  • Saint-Herblain
  • St Albans
  • Toulouse
  • Truro
  • València
Trial Identifier:

NCT03916744 2018-003798-85 GO40987

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT03916744 , GO40987 , 2018-003798-85 Trial Identifier
      Female Gender
      ≥18 Years Age
      No Healthy Volunteers

      This clinical trial was done to study a new medicine called, “giredestrant”, also known as “GDC-9545”, for the treatment of patients with “ER+ positive breast cancer”. This study was done to find out whether giredestrant was effective in slowing down ER+ breast cancer cell growth in patients. Researchers also wanted to find out if it was safe and if patients could tolerate this medicine. Seventy-five patients with HER+ breast cancer signed up for the study at 15 study centers across five countries.

      Trial Summary

      This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of giredestrant in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

      Genentech, Inc. Sponsor
      Phase 1 Phase
      NCT03916744 , GO40987 , 2018-003798-85 Trial Identifier
      Giredestrant, Surgery Treatments
      Breast Cancer Condition
      Official Title

      A Phase I, Multicenter, Open-Label Preoperative, Short-Term Window Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer

      Eligibility Criteria

      Female Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Ability to comply with the study protocol, in the investigator's judgment
      • Histologically confirmed invasive breast carcinoma, with all of the following characteristics: Primary tumor greater than or equal to (≥)1.5 centimeters (cm) in largest diameter by ultrasound; Stage I-III operable breast cancer; Documentation confirming the absence of distant metastasis (M0) as determined by institutional practice.
      • ER-positive tumor and HER2-negative breast cancer as per local laboratory testing
      • Postmenopausal status
      • Breast cancer eligible for primary surgery
      • Submission of a representative tumor tissue specimen
      • Eastern Cooperative Oncology Group (ECOG) Performance Status less than or equal to (≤)1
      • Adequate organ function
      Exclusion Criteria
      • Diagnosis of inflammatory breast cancer
      • Diagnosis of bilateral breast cancer
      • Concurrent use of hormone replacement therapies
      • Previous systemic or local treatment for the primary breast cancer currently under investigation
      • Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days prior to study entry
      • Current treatment with any systemic anti-cancer therapies
      • Major surgery within 4 weeks prior to enrollment
      • Radiation therapy within 2 weeks prior to enrollment
      • Diagnosis of any secondary malignancy within 3 years prior to enrollment, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
      • Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
      • Known HIV infection
      • Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, including active viral or other hepatitis, current alcohol abuse, or cirrhosis
      • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study
      • History of allergy to giredestrant or any of its excipients
      • Any condition requiring anti-coagulants, such as warfarin, heparin, or thrombolytic drugs
      • History of documented hemorrhagic diathesis or coagulopathy
      • History or presence of symptomatic bradycardia or sick sinus syndrome
      • Baseline heart rate ≤55 beats per minute (bpm) prior to enrollment
      • History or presence of an abnormal electrocardiogram (ECG) that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third-degree heart block, or evidence of prior myocardial infarction
      • QT interval corrected through use of Fridericia's formula (QTcF) >470 milliseconds demonstrated by at least two ECGs >30 minutes apart
      • History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias such as structural heart disease, coronary heart disease, clinically significant electrolyte abnormalities, or family history of sudden unexplained death or long QT syndrome
      • Current treatment with medications that are well known to prolong the QT interval
      • History or presence of uncontrolled hypothyroidism
      • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now